May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR conference regarding the MiStent Drug-Eluting Coronary Stent System (MiStent DES), an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. The data will be presented in Paris, France May 18 in a presentation titled "MiStent DES: A Novel Third Generation DES with a Fully-Absorbable Coating and Enhanced Drug Delivery Capabilities."
In a porcine coronary model, data show continuous and controlled release of sirolimus, with the MiStent DES coating being eliminated from the stent within 45-60 days, and fully absorbed in the tissue by 90 days following implant. Preclinical studies additionally demonstrated a positive indication of safety with lower inflammation observed from the MiStent DES compared to the bare metal Abbott Multi-Link Vision coronary stent at 30 and 90 days in the challenging overlapping stents implant configuration.
Clinical trials of the MiStent DES include DESSOLVE I, a study of 30 patients with documented stable or unstable angina pectoris or ischemia, which completed enrollment earlier this year. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent. DESSOLVE II is an ongoing multi-center study of approximately 270 patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor Sprint DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm long stent.
For more information: www.micell.com
May 06, 2026 
